Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 28 Feb 2011 |
| Genmab Announces Year End 2010 Financial Results and 2011 Guidance | 28 Feb 2011 |
| Genmab to Attend Credit Suisse One-On-One Healthcare Conference | 24 Feb 2011 |
| Arzerra Fourth Quarter and Full Year 2010 Net Sales Figures | 3 Feb 2011 |
| Genmab Provides Detailed Pipeline and Technology Update at Today's R&D Day | 20 Jan 2011 |